Related Experiment Video
Updated: Jun 8, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Rifampicin-induced thrombocytopenia
Ajay Kumar Verma1, Arpita Singh, Amol Chandra
1Department of TB and Chest Diseases, S.N. Medical College, Agra - 282 002, India.
Tuberculosis drug treatment faces challenges like side effects and resistance. This case highlights rifampicin-induced thrombocytopenia, a rare but serious adverse drug reaction requiring medical attention.
Area of Science:
- Medicine
- Pharmacology
- Infectious Diseases
Background:
- Tuberculosis treatment presents challenges including adverse drug effects, patient compliance, and drug resistance.
- Thrombocytopenia is a rare but severe adverse effect linked to specific anti-tuberculosis medications.
Purpose of the Study:
- To report a case of thrombocytopenia induced by rifampicin.
- To emphasize the importance of recognizing and managing this rare adverse drug reaction.
Main Methods:
- Case report detailing a patient experiencing thrombocytopenia.
- Review of literature on drug-induced thrombocytopenia in tuberculosis treatment.
Main Results:
- The patient developed thrombocytopenia attributed to rifampicin.
- This adverse effect, though uncommon, necessitates clinical vigilance.
Conclusions:
- Rifampicin can cause potentially fatal thrombocytopenia in susceptible individuals.
- Awareness and prompt management are crucial for patients undergoing tuberculosis therapy.
Related Concept Videos
Rocky Mountain Spotted Fever
Cryptococcal Meningitis
Pharmacokinetics: Drug–Drug Interactions
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Inhibitors of Bacterial Protein Synthesis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...